(Q33846408)

English

Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

unstable angina

1 reference

based on heuristic

inferred from title

myocardial infarction

1 reference

based on heuristic

inferred from title

author name string

Antman EM

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Fox KM

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

1 March 2000

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

American Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

139

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

461-475

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Unstable angina. A classification

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Diagnosing and managing unstable angina. Agency for Health Care Policy and Research

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Management strategies for a better outcome in unstable coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Insights into the pathogenesis of acute ischemic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Unstable angina: prognosis of the individual patient.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Prospective study of the role of cardiac troponin T in patients admitted with unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

The coagulation cascade: initiation, maintenance, and regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Aspirin, heparin, or both to treat acute unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Direct thrombin inhibitors in cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders

2 references

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infar

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Heparin-induced thrombocytopenia. Pathogenesis, frequency, avoidance and management

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Seminars in thrombosis, thrombolysis and vascular biology. 3. Platelet activity in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Adverse haematological effects of ticlopidine. Prevention, recognition and management

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Glycoprotein IIb/IIIa integrin blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Statin trials and goals of cholesterol-lowering therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Inv

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Trends in the quality of care for Medicare beneficiaries admitted to the hospital with unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Improving care for unstable angina patients in a multiple hospital project sponsored by a federally designated quality improvement organization

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Unstable angina: specialty-related disparities in implementation of practice guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events i

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990090-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0002-8703(00)90090-5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33846408&oldid=1638620428"